Five-year survival does not equal cure in non–small cell lung cancer: A Surveillance, Epidemiology, and End Results–based analysis of variables affecting 10- to 18-year survival

Hubbard, Matthew; Fu, Pingfu; Margevicius, Seunghee; Dowlati, Afshin; Linden, Philip A.

doi:10.1016/j.jtcvs.2012.01.078

Cited by 48 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonsmall-cell lung cancer (NSCLC) accounts for 85–90% of lung cancer cases with a 5-year survival rate of 15% (Siegel, Naishadham, & Jemal, 2012). Metastatic spread accounts for >70% of NSCLC deaths with the major sites of NSCLC metastasis being brain, bone, adrenal gland, and liver (Hubbard, Fu, Margevicius, Dowlati, & Linden, 2012; Murthy et al, 2010; Saintigny & Burger, 2012; Triano, Deshpande, & Gettinger, 2010). Numerous studies have established a strong correlation between CXCR4 expression and poor prognosis in NSCLC (Burger, Stewart, Wald, & Peled, 2011; Saintigny & Burger, 2012; Spano et al, 2004; Su et al, 2005; Wagner et al, 2009).…”

Section: Role Of Cxcr4 In Cancermentioning

confidence: 99%

The Intricate Role of CXCR4 in Cancer

Chatterjee

Azad

Nimmagadda

2014

Advances in Cancer Research

551

530

View full text Add to dashboard Cite

Chemokines mediate numerous physiological and pathological processes related primarily to cell homing and migration. The chemokine CXCL12, also known as stromal cell-derived factor-1, binds the G-protein-coupled receptor CXCR4, which, through multiple divergent pathways, leads to chemotaxis, enhanced intracellular calcium, cell adhesion, survival, proliferation, and gene transcription. CXCR4, initially discovered for its involvement in HIV entry and leukocytes trafficking, is overexpressed in more than 23 human cancers. Cancer cell CXCR4 overexpression contributes to tumor growth, invasion, angiogenesis, metastasis, relapse, and therapeutic resistance. CXCR4 antagonism has been shown to disrupt tumor–stromal interactions, sensitize cancer cells to cytotoxic drugs, and reduce tumor growth and metastatic burden. As such, CXCR4 is a target not only for therapeutic intervention but also for noninvasive monitoring of disease progression and therapeutic guidance. This review provides a comprehensive overview of the biological involvement of CXCR4 in human cancers, the current status of CXCR4-based therapeutic approaches, as well as recent advances in noninvasive imaging of CXCR4 expression.

show abstract

Section: Role Of Cxcr4 In Cancermentioning

confidence: 99%

The Intricate Role of CXCR4 in Cancer

Chatterjee

Azad

Nimmagadda

2014

Advances in Cancer Research

551

530

View full text Add to dashboard Cite

show abstract

“…The anticipated implementation of nation-wide lung cancer screening programs will increase the proportion of patients diagnosed in early disease stages permitting such patients to undergo surgical resection, which is considered the best therapeutic approach 9. Nonetheless, the five years survival rates of these surgically treated patient, with or without the addition of adjuvant chemotherapy or radiotherapy is approximately 50% 10, 11. Following primary tumor development the disease tends to progress along three distinct, yet often concomitantly occurring pathways: 1.…”

Section: Introduction - Lung Cancermentioning

confidence: 99%

CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential

Wald

Shapira²,

Izhar³

2013

Theranostics

115

View full text Add to dashboard Cite

Lung cancer is the second most common malignancy and the leading cause of cancer-related death in the western world. Moreover, despite advances in surgery, chemotherapy and radiotherapy, the death rate from lung cancer remains high and the reported overall five-year survival rate is only 15%. Thus, novel treatments for this devastating disease are urgently needed. Chemokines, a family of 48 chemotactic cytokines interacts with their 7 transmembrane G-protein-coupled receptors, to guide immune cell trafficking in the body under both physiologic and pathologic conditions. Tumor cells, which express a relatively restricted repertoire of chemokine and chemokine receptors, utilize and manipulate the chemokine system in a manner that benefits both local tumor growth and distant dissemination. Among the 19 chemokine receptors, CXCR4 is the receptor most widely expressed by malignant tumors and whose role in tumor biology is most thoroughly studied. The chemokine CXCL12, which is the sole ligand of CXCR4, is highly expressed in primary lung cancer as well as in the bone marrow, liver, adrenal glands and brain, which are all sites for lung cancer metastasis. This review focuses on the pathologic role of the CXCR4/CXCL12 axis in NSCLC and on the potential therapeutic implication of targeting this axis for the treatment of NSCLC.

show abstract

“…Each year, more than one million individuals die worldwide from lung cancer, making it the leading cause of cancer-related deaths, and the 5-year survival rate is among the lowest of all cancers (Wu et al, 2011;Hubbard et al, 2012). A major challenge is the prevailing lack of specific biomarkers for detecting and monitoring lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer

Tang¹,

Shen²,

Wang³

et al. 2013

European Journal of Cancer Prevention

112

View full text Add to dashboard Cite

Recent diagnostic procedure advances have considerably improved early lung cancer detection. However, the invasive, unpleasant, and inconvenient nature of current diagnostic procedures limits their application. There is a great need for novel noninvasive biomarkers for early lung cancer diagnosis. In the present study, we aimed to determine whether microRNA (miRNA) blood signatures are suitable for early detection of lung cancer. Using quantitative reverse transcriptase PCR analysis, we first selected and identified three aberrant plasma expression miRNAs (miR-21, miR-145, and miR-155) in a training set of 62 patients and 60 healthy smokers to define a panel that had high diagnostic efficiency for lung cancer. Then, we validated the detective ability of this miRNA panel in a testing set of 34 malignant tumor patients, 30 patients with benign pulmonary nodules and 32 healthy smokers. In the training set, miR-21 and miR-155 showed higher plasma expression levels, whereas miR-145 showed a lower expression level in patients with malignant cancer, compared with healthy controls (P ≤ 0.001). The three miRNAs used in combination produced the area under receiver operating characteristic curve at 0.847, which helped distinguish lung cancer from healthy smokers with 69.4% sensitivity and 78.3% specificity. A logistic regression model with the best prediction was constructed on the basis of miR-21, miR-145, and miR-155. Validation of the miRNA panel in the testing set confirmed their diagnostic value, which yields a significant improvement over any single one. Plasma miR-21, miR-145, and miR-155 have strong potential as novel noninvasive biomarkers for early detection of lung cancer.

show abstract

Five-year survival does not equal cure in non–small cell lung cancer: A Surveillance, Epidemiology, and End Results–based analysis of variables affecting 10- to 18-year survival

Cited by 48 publications

References 17 publications

The Intricate Role of CXCR4 in Cancer

The Intricate Role of CXCR4 in Cancer

CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential

Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer

Contact Info

Product

Resources

About